Contact Us
 | FCH-IM/PAHO
525 23rd St. NW
Washington, D.C. 20037
Phone: 202.974.3510
Fax: 202.974.3635
E-mail: FCH-IM |
|
Featured Items
|
FINAL STATEMENT by (PAHO/WHO) on Investigation of Serious Adverse Events in Peru Following Receipt of Yellow Fever Vaccine Produced by Bio-Manguinhos, Brazil
This PAHO/WHO statement provides results of the investigation of serious adverse events that occurred in October 2007 following administration of yellow fever vaccine (17DD sub-strain) manufactured by Bio-Manguinhos, Brazil.
A previous PAHO/WHO statement on the reported events was issued on 2 November 2007 and recommended temporary suspension of specific lots of the vaccine.
More in PDF »
|
|
|
Final Report of the AMR RCC, Brasilia, Brazil - 28-29 February 2008
Final Report of the Second Meeting of the American Regional Commission for Certification of Poliovirus Laboratory Containment and Verification of Poliofree Status (AMR RCC), Brasilia, Brazil - 28-29 February 2008 More in PDF »
|
|
|
Immunization Newsletter, February 2008, Vol XXX, Number 1
IN THIS ISSUE: 27th Pan American Sanitary Conference; Paving the Road for Pneumococcal Vaccine Introduction; Aide-memoire for Prevention of Freeze
Damage to Vaccines; Vaccine Freezing: Bolivia Study; Sentinel Surveillance System of Diarrhea due to Rotavirus in Paraguay; PAHO Revolving Fund: Vaccine Prices,2008 More in PDF »
|
|
|
CDC Travelers' Health: In the News-Yellow Fever Vaccine Adverse Events in Peru
(Updated: November 19, 2007) Four laboratory-confirmed deaths in Peru have been associated with receipt of yellow fever vaccine. The vaccine was administered as part of a mass immunization campaign after the recent earthquake in Peru.
Yellow Fever
|
|
| More Featured Items » |
|
|
